iShares MSCI Malaysia ETF vs Cassava Sciences Inc — how do they compare? iShares MSCI Malaysia ETF trades at $27.97, while Cassava Sciences Inc trades at $1.1 (market cap $53.14M). The key difference: iShares MSCI Malaysia ETF is trading nearer its 52-week high, Cassava Sciences Inc nearer its low. Which is the better fit depends on your goals.
| EWM | FLNA | |
|---|---|---|
Sector | Broad Market / Factor | Health |
52-Week High | $30.42 | $4.64 |
52-Week Low | $23.49 | $1.09 |
Market Cap | — | $53.14M |
Enterprise Value | — | -$33.43M |
Signals from Pluang's Aura AI — not financial advice
EWM (iShares MSCI Malaysia ETF) trades at $28.005, down 0.3% on the day, with technical indicators showing a bullish bias despite overbought RSI readings. The ETF provides concentrated exposure to Malaysia's financial (54%) and industrial (21%) sectors, benefiting from the country's data center expansion, semiconductor ambitions, and tourism initiatives. Recent news highlights Malaysia's energy diversification efforts amid regional power demand surges.
The outlook remains constructive given Malaysia's structural growth drivers, though investors face currency risk, regional geopolitical tensions, and dependence on global semiconductor demand. Current technical strength suggests near-term upside potential, but elevated RSI levels warrant caution for entry timing.
FLNA trades at $1.06, down 2.75% today, with a bearish technical signal from moving averages but neutral oscillators. The stock shows a low P/B of 0.78, yet profitability metrics are negative, including a -79.59% ROE and -$90.97M net income for 2025. Recent Q1 2026 earnings beat expectations, and analyst consensus is 66.7% buy. News highlights Q1 financial results and a scientific presentation on TSC-related epilepsy therapies.
Outlook remains speculative due to persistent losses and negative cash flows, offset by strong analyst support and recent earnings beats. Key risks include funding needs for drug development and competitive pressures, while potential upside hinges on clinical progress in TSC-related epilepsy treatments.
Trailing returns across standard periods
EWM tracks the MSCI Malaysia Index, providing exposure to the Malaysian equity market. It offers a diversified portfolio of large and mid-sized companies across various sectors in Malaysia.
Read more on EWM →Cassava Sciences Inc is a clinical-stage biotechnology company engaged in developing a scientific approach for the treatment and detection of Alzheimer's disease. Its therapeutic product candidate is called simufilam, and it is a novel treatment for Alzheimer's disease
Read more on FLNA →